)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Genovis
Genovis (GENO) investor relations material
Genovis Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary23 Jul, 2026
Executive summary
Achieved strategic expansion with the acquisition of KPL ApS, broadening the proteomics portfolio and customer base.
Launched new products, including AlligBAITOR for antibody enrichment, and strengthened underlying profitability despite one-off acquisition costs.
Product sales, excluding services, grew by approximately 20% year-over-year, with genomics delivering its best quarter to date.
Financial highlights
Q2 net sales reached SEK 34,316 thousand, up 19% year-over-year (21% currency-adjusted); H1 net sales were SEK 67,823 thousand, up 11% (19% currency-adjusted).
Q2 EBITDA was SEK 6,844 thousand, impacted by SEK 3,492 thousand in acquisition costs; adjusted EBITDA was SEK 10,336 thousand.
Q2 EBIT was SEK 2,824 thousand; adjusted EBIT was SEK 6,316 thousand.
Q2 earnings per share were SEK 0.02 (adjusted SEK 0.07); H1 EPS was SEK 0.08 (adjusted SEK 0.14).
Q2 cash flow from operating activities was SEK 7,906 thousand; H1 cash flow was SEK 24,417 thousand.
Outlook and guidance
Positioned for further advances in new products and sales in 2026, with most development projects on track.
Business opportunities and operational capacity assessed as good, though external geopolitical and macroeconomic factors remain uncertainties.
Status of ADC clinical program evaluations
SEQguard traction through Plasmidsaurus
Expected synergies from the KPL acquisition
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Genovis
- EBITDA margin rose to 28.4% on 4% sales growth, with strong cash flow and new product launches.GENO
Q1 2026 - Strong Q4 sales growth and robust margins, boosted by a major order and Sequrna AB acquisition.GENOQ4 2025
- Sales dipped in Q3, but pharma growth, Sequrna acquisition, and a major order boost outlook.GENOQ3 2025
- Enzyme business delivered strong growth and profitability, expanding strategically into genomics.GENOQ2 2025
- Record enzyme sales and profitability in Q3 2024, fueled by strategic focus and innovation.GENOQ3 2024
- Flat Q2 sales, lower H1 profit, strategic antibody divestment, and SEQURNA investment.GENOQ2 2024
- Record enzyme business growth and strong profit despite currency headwinds.GENOQ1 2025
- Enzyme business sales surged 21% in Q4, with robust margins and a strengthened cash position.GENOQ4 2024
Next Genovis earnings date
Q3 202610 Nov, 2026
Genovis
Next Genovis earnings date
Q3 202610 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage